Cui Z, Ye G, Yu W, Wang Z, Kong F, Ren L
Department of Hepatobiliary and Pancreatic Surgery, Qinghai University Affiliated Hospital, Xining, Qinghai 810012, China.
Qinghai University Medical School, Xining, Qinghai 810012, China.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2022 Aug 30;35(1):104-110. doi: 10.16250/j.32.1374.2022075.
Alveolar echinococcosis, caused by infection, is a highly deadly zoonotic parasitic disease. As a benzimidazole compound, albendazole has a strong and broad-spectrum anti-parasitic action. For alveolar echinococcosis patients that are unwilling to receive surgical treatment, lose the timing for surgery, or are intolerant to surgery due to poor physical status, administration of albendazole may delay disease progression. Recently, a large number of advances have been achieved in experimental studies on alveolar echinococcosis. In order to increase the understanding of the therapeutic efficacy of albendazole for alveolar echinococcosis, this review summarizes the advances in albendazole treatment for alveolar echinococcosis, so as to provide insights into the clinical treatment of alveolar echinococcosis with albendazole.
泡型包虫病是一种由感染引起的高度致命的人畜共患寄生虫病。阿苯达唑作为一种苯并咪唑类化合物,具有强大且广谱的抗寄生虫作用。对于不愿接受手术治疗、错过手术时机或因身体状况不佳而不耐受手术的泡型包虫病患者,使用阿苯达唑可能会延缓疾病进展。近年来,泡型包虫病的实验研究取得了大量进展。为了增进对阿苯达唑治疗泡型包虫病疗效的了解,本综述总结了阿苯达唑治疗泡型包虫病的研究进展,以期为临床应用阿苯达唑治疗泡型包虫病提供参考。